HHS Reg Reform Committee To Discuss Adverse Event Reporting June 10
Executive Summary
HHS' advisory committee on regulatory reform will discuss adverse event reporting during its June 10-11 meeting in Minneapolis, Minn
You may also be interested in...
HHS Reg Reform Panel To Review FDA Example Of “Best Practices”
The HHS Advisory Committee on Regulatory Reform will hear a presentation from the Center for Drug Evaluation & Research as an example of "best practices" during its inaugural meeting
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials